SOX11 and Epithelial-Mesenchymal Transition in Metastatic Serous Ovarian Cancer
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patient Collective
2.2. Immunohistochemical Analysis
2.3. Statistical Analysis
3. Results
3.1. Patients’ Characteristics
3.2. Immunohistochemical Expression of E-Cadherin in Ovarian Serous Carcinoma
3.3. Immunohistochemical Expression of Vimentin in Ovarian Serous Carcinoma
3.4. Immunohistochemical Expression of SOX11 in Ovarian Serous Carcinoma
3.5. Associations between the Examined Molecules
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- American Cancer Society. Key Statistics for Ovarian Cancer: American Cancer Society. 2023. Available online: https://www.cancer.org/cancer/types/ovarian-cancer/about/key-statistics.html (accessed on 15 July 2023).
- Prat, J. Ovarian carcinomas: Five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012, 460, 237–249. [Google Scholar] [CrossRef] [PubMed]
- Seebacher, V.; Reinthaller, A.; Koelbl, H.; Concin, N.; Nehoda, R.; Polterauer, S. The Impact of the Duration of Adjuvant Chemotherapy on Survival in Patients with Epithelial Ovarian Cancer—A Retrospective Study. PLoS ONE 2017, 12, e0169272. [Google Scholar] [CrossRef] [PubMed]
- Psilopatis, I.; Sykaras, A.G.; Mandrakis, G.; Vrettou, K.; Theocharis, S. Patient-Derived Organoids: The Beginning of a New Era in Ovarian Cancer Disease Modeling and Drug Sensitivity Testing. Biomedicines 2022, 11, 1. [Google Scholar] [CrossRef] [PubMed]
- American Cancer Society. Survival Rates for Ovarian Cancer: American Cancer Society. 2023. Available online: https://www.cancer.org/cancer/types/ovarian-cancer/detection-diagnosis-staging/survival-rates.html (accessed on 15 July 2023).
- American Cancer Society. Tests for Ovarian Cancer: American Cancer Society. 2022. Available online: https://www.cancer.org/cancer/types/ovarian-cancer/detection-diagnosis-staging/how-diagnosed.html (accessed on 15 July 2023).
- Tossetta, G.; Fantone, S.; Montanari, E.; Marzioni, D.; Goteri, G. Role of NRF2 in Ovarian Cancer. Antioxidants 2022, 11, 663. [Google Scholar] [CrossRef]
- Tossetta, G. Metformin Improves Ovarian Cancer Sensitivity to Paclitaxel and Platinum-Based Drugs: A Review of In Vitro Findings. Int. J. Mol. Sci. 2022, 23, 12893. [Google Scholar] [CrossRef]
- Kalluri, R.; Neilson, E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Investig. 2003, 112, 1776–1784. [Google Scholar] [CrossRef]
- Kalluri, R.; Weinberg, R.A. The basics of epithelial-mesenchymal transition. J. Clin. Investig. 2009, 119, 1420–1428. [Google Scholar] [CrossRef]
- Yang, J.; Weinberg, R.A. Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev. Cell 2008, 14, 818–829. [Google Scholar] [CrossRef]
- Brabletz, T.; Jung, A.; Reu, S.; Porzner, M.; Hlubek, F.; Kunz-Schughart, L.A.; Knuechel, R.; Kirchner, T. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc. Natl. Acad. Sci. USA 2001, 98, 10356–10361. [Google Scholar] [CrossRef]
- Fidler, I.J.; Poste, G. The “seed and soil” hypothesis revisited. Lancet Oncol. 2008, 9, 808. [Google Scholar] [CrossRef]
- Thiery, J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2, 442–454. [Google Scholar] [CrossRef] [PubMed]
- Dongre, A.; Weinberg, R.A. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat. Rev. Mol. Cell Biol. 2019, 20, 69–84. [Google Scholar] [CrossRef] [PubMed]
- Shibue, T.; Weinberg, R.A. EMT, CSCs, and drug resistance: The mechanistic link and clinical implications. Nat. Rev. Clin. Oncol. 2017, 14, 611–629. [Google Scholar] [CrossRef] [PubMed]
- Fares, J.; Fares, M.Y.; Khachfe, H.H.; Salhab, H.A.; Fares, Y. Molecular principles of metastasis: A hallmark of cancer revisited. Signal Transduct. Target. Ther. 2020, 5, 28. [Google Scholar] [CrossRef]
- Lefebvre, V.; Dumitriu, B.; Penzo-Mendez, A.; Han, Y.; Pallavi, B. Control of cell fate and differentiation by Sry-related high-mobility-group box (Sox) transcription factors. Int. J. Biochem. Cell Biol. 2007, 39, 2195–2214. [Google Scholar] [CrossRef]
- Penzo-Mendez, A.I. Critical roles for SoxC transcription factors in development and cancer. Int. J. Biochem. Cell Biol. 2010, 42, 425–428. [Google Scholar] [CrossRef]
- de Bont, J.M.; Kros, J.M.; Passier, M.M.; Reddingius, R.E.; Sillevis Smitt, P.A.; Luider, T.M.; den Boer, M.L.; Pieters, R. Differential expression and prognostic significance of SOX genes in pediatric medulloblastoma and ependymoma identified by microarray analysis. Neuro Oncol. 2008, 10, 648–660. [Google Scholar] [CrossRef]
- Jay, P.; Goze, C.; Marsollier, C.; Taviaux, S.; Hardelin, J.P.; Koopman, P.; Berta, P. The human SOX11 gene: Cloning, chromosomal assignment and tissue expression. Genomics 1995, 29, 541–545. [Google Scholar] [CrossRef]
- Harrison, G.; Hemmerich, A.; Guy, C.; Perkinson, K.; Fleming, D.; McCall, S.; Cardona, D.; Zhang, X. Overexpression of SOX11 and TFE3 in Solid-Pseudopapillary Neoplasms of the Pancreas. Am. J. Clin. Pathol. 2017, 149, 67–75. [Google Scholar] [CrossRef]
- Weigle, B.; Ebner, R.; Temme, A.; Schwind, S.; Schmitz, M.; Kiessling, A.; Rieger, M.A.; Schackert, G.; Schackert, H.K.; Rieber, E.P. Highly specific overexpression of the transcription factor SOX11 in human malignant gliomas. Oncol. Rep. 2005, 13, 139–144. [Google Scholar] [CrossRef]
- Zhang, L.N.; Cao, X.; Lu, T.X.; Fan, L.; Wang, L.; Xu, J.; Zhang, R.; Zou, Z.J.; Wu, J.Z.; Li, J.Y.; et al. Polyclonal antibody targeting SOX11 cannot differentiate mantle cell lymphoma from B-cell non-Hodgkin lymphomas. Am. J. Clin. Pathol. 2013, 140, 795–800. [Google Scholar] [CrossRef] [PubMed]
- Shepherd, J.H.; Uray, I.P.; Mazumdar, A.; Tsimelzon, A.; Savage, M.; Hilsenbeck, S.G.; Brown, P.H. The SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression. Oncotarget 2016, 7, 13106–13121. [Google Scholar] [CrossRef] [PubMed]
- Oliemuller, E.; Newman, R.; Tsang, S.M.; Foo, S.; Muirhead, G.; Noor, F.; Haider, S.; Aurrekoetxea-Rodriguez, I.; Vivanco, M.D.; Howard, B.A. SOX11 promotes epithelial/mesenchymal hybrid state and alters tropism of invasive breast cancer cells. eLife 2020, 9, e58374. [Google Scholar] [CrossRef]
- Meinhold-Heerlein, I.; Fotopoulou, C.; Harter, P.; Kurzeder, C.; Mustea, A.; Wimberger, P.; Hauptmann, S.; Sehouli, J.; Kommission Ovar of the AGO. Statement by the Kommission Ovar of the AGO: The New FIGO and WHO Classifications of Ovarian, Fallopian Tube and Primary Peritoneal Cancer. Geburtshilfe Frauenheilkd. 2015, 75, 1021–1027. [Google Scholar] [CrossRef] [PubMed]
- Huh, S.; Kang, C.; Park, J.E.; Nam, D.; Kim, S.I.; Seol, A.; Choi, K.; Hwang, D.; Yu, M.H.; Chung, H.H.; et al. Novel Diagnostic Biomarkers for High-Grade Serous Ovarian Cancer Uncovered by Data-Independent Acquisition Mass Spectrometry. J. Proteome Res. 2022, 21, 2146–2159. [Google Scholar] [CrossRef] [PubMed]
- Atallah, G.A.; Abd Aziz, N.H.; Teik, C.K.; Shafiee, M.N.; Kampan, N.C. New Predictive Biomarkers for Ovarian Cancer. Diagnostics 2021, 11, 465. [Google Scholar] [CrossRef]
- Loh, C.Y.; Chai, J.Y.; Tang, T.F.; Wong, W.F.; Sethi, G.; Shanmugam, M.K.; Chong, P.P.; Looi, C.Y. The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges. Cells 2019, 8, 1118. [Google Scholar] [CrossRef]
- Na, T.Y.; Schecterson, L.; Mendonsa, A.M.; Gumbiner, B.M. The functional activity of E-cadherin controls tumor cell metastasis at multiple steps. Proc. Natl. Acad. Sci. USA 2020, 117, 5931–5937. [Google Scholar] [CrossRef]
- Loret, N.; Denys, H.; Tummers, P.; Berx, G. The Role of Epithelial-to-Mesenchymal Plasticity in Ovarian Cancer Progression and Therapy Resistance. Cancers 2019, 11, 838. [Google Scholar] [CrossRef]
- Brennan, D.J.; Ek, S.; Doyle, E.; Drew, T.; Foley, M.; Flannelly, G.; O’Connor, D.P.; Gallagher, W.M.; Kilpinen, S.; Kallioniemi, O.P.; et al. The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer. Eur. J. Cancer 2009, 45, 1510–1517. [Google Scholar] [CrossRef]
- Sernbo, S.; Gustavsson, E.; Brennan, D.J.; Gallagher, W.M.; Rexhepaj, E.; Rydnert, F.; Jirstrom, K.; Borrebaeck, C.A.; Ek, S. The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation. BMC Cancer 2011, 11, 405. [Google Scholar] [CrossRef] [PubMed]
- Davidson, B.; Holth, A.; Hellesylt, E.; Tan, T.Z.; Huang, R.Y.; Trope, C.; Nesland, J.M.; Thiery, J.P. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions. Hum. Pathol. 2015, 46, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Fang, G.; Liu, J.; Wang, Q.; Huang, X.; Yang, R.; Pang, Y.; Yang, M. MicroRNA-223-3p Regulates Ovarian Cancer Cell Proliferation and Invasion by Targeting SOX11 Expression. Int. J. Mol. Sci. 2017, 18, 1208. [Google Scholar] [CrossRef] [PubMed]
- Xiao, Y.; Xie, Q.; Qin, Q.; Liang, Y.; Lin, H.; Zeng, D. Upregulation of SOX11 enhances tamoxifen resistance and promotes epithelial-to-mesenchymal transition via slug in MCF-7 breast cancer cells. J. Cell. Physiol. 2020, 235, 7295–7308. [Google Scholar] [CrossRef]
- Saitoh, M. Involvement of partial EMT in cancer progression. J. Biochem. 2018, 164, 257–264. [Google Scholar] [CrossRef]
- Norgard, R.J.; Pitarresi, J.R.; Maddipati, R.; Aiello-Couzo, N.M.; Balli, D.; Li, J.; Yamazoe, T.; Wengyn, M.D.; Millstein, I.D.; Folkert, I.W.; et al. Calcium signaling induces a partial EMT. EMBO Rep. 2021, 22, e51872. [Google Scholar] [CrossRef]
Patient Characteristics | Median Value | Value Range |
---|---|---|
Age (in years) | 61.5 | 46–92 |
FIGO stage | Number of patients | Percentage |
I | 7 | 23% |
II | 3 | 10% |
III | 11 | 37% |
IV | 9 | 30% |
Tumor grade | Number of patients | Percentage |
Low grade | 5 | 17% |
High grade | 25 | 83% |
Metastasis | Number of patients | Percentage |
Metastatic cancer | 15 | 50% |
Nonmetastatic cancer | 15 | 50% |
Residual disease | ||
None/minimal | 25 | 83% |
>2 cm | 5 | 17% |
Event | Number of patients | Percentage |
Death due to disease | 6/21 (follow-up: 3.4–35 months) | 29% |
Censored | 15/21 (follow-up: 5–68 months) | 71% |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Psilopatis, I.; Schaefer, J.I.; Arsenakis, D.; Bolovis, D.; Levidou, G. SOX11 and Epithelial-Mesenchymal Transition in Metastatic Serous Ovarian Cancer. Biomedicines 2023, 11, 2540. https://doi.org/10.3390/biomedicines11092540
Psilopatis I, Schaefer JI, Arsenakis D, Bolovis D, Levidou G. SOX11 and Epithelial-Mesenchymal Transition in Metastatic Serous Ovarian Cancer. Biomedicines. 2023; 11(9):2540. https://doi.org/10.3390/biomedicines11092540
Chicago/Turabian StylePsilopatis, Iason, Jule Ida Schaefer, Dimitrios Arsenakis, Dimitrios Bolovis, and Georgia Levidou. 2023. "SOX11 and Epithelial-Mesenchymal Transition in Metastatic Serous Ovarian Cancer" Biomedicines 11, no. 9: 2540. https://doi.org/10.3390/biomedicines11092540